Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Placement On China's New Essential Drugs List Bring Boon Or Bane? Pharma Execs Debate The Issue

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Senior leaders at pharmaceutical outfits across China and the globe are awaiting China's issuing of its new streamlined Essential Drugs List, some with wonder and some with trepidation

You may also be interested in...



Powerful Chinese Government Commission Set To Issue Price Caps For Essential Drug List Medicines

BEIJING - China's powerful National Development and Reform Commission, which has a virtually unrestricted purview over setting prices for medicines that are included on the country's Essential Drug List, is in the final stages of determining caps for every item on the newly revised list

Powerful Chinese Government Commission Set To Issue Price Caps For Essential Drug List Medicines

BEIJING - China's powerful National Development and Reform Commission, which has a virtually unrestricted purview over setting prices for medicines that are included on the country's Essential Drug List, is in the final stages of determining caps for every item on the newly revised list

China Paring Down Essential Medicines List In Sweeping Health System Reforms

[Editor's note: This is part three in a new series on China's wide-ranging plans to reform the country's health system, including its hospitals, insurance schemes, and access to medicines. Part one in the series appeared in PharmAsia News Oct. 30, 2008, and part two appeared Nov. 13, 2008.]

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel